CML ELN Guidelines 2020

The landscape for CML has changed profoundly since the ELN 2013 guidelines were first published1

• Life expectancy for Ph+ BCR-ABL1 CP-CML is now close to age-matched individuals

• Several TKIs are approved for CML treatment

• Treatment choice is determined considering efficacy, tolerability and toxicity

• Since 2013, more focus has been put on improving QoL, particularly avoiding long-term toxicity

• Management goals and therapies continue to evolve

The ELN convened an international expert panel to update the recommendations

ELN 2020 guidelines were developed to guide clinicians, as a consensus of the panel supported by high-quality, peer-reviewed evidence

ELN 2020 guideline recommendations reflect near-normal life expectancy of patients with CML and the need to minimise long-term toxicities and improve quality of life

To download a summary of the changes between the 2013 and 2020 ELN guidelines and to view the recommendations for BOSULIF, please click here

 

Reference:
1
: Hochhaus A, et al. Leukemia 2020; doi: 10.1038/s41375-020-0776-2

PP-BOS-GBR-1027. January 2021